Product
NT-501
7 clinical trials
5 indications
Indication
Macular Telangiectasia Type 2Indication
Retinitis PigmentosaIndication
Usher syndrome type 2Indication
Usher syndrome type 3Indication
GlaucomaClinical trial
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and DensityStatus: Completed, Estimated PCD: 2019-07-01
Clinical trial
Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants With Macular Telangiectasia Type 2Status: Completed, Estimated PCD: 2022-12-23
Clinical trial
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Multicenter Study to Determine the Safety and Efficacy of NT-501 Utilizing the Medica Membrane in Macular Telangiectasia Type 2Status: Not yet recruiting, Estimated PCD: 2026-04-27
Clinical trial
A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of GlaucomaStatus: Active (not recruiting), Estimated PCD: 2024-08-15
Clinical trial
A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of GlaucomaStatus: Recruiting, Estimated PCD: 2024-08-15